TrialChinese journal of cancer2017

Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.

Rui-Hua Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.